1,160 results on '"Popat, Sanjay"'
Search Results
2. MesoGraph: Automatic Profiling of Malignant Mesothelioma Subtypes from Histological Images
3. Updates in Management of Malignant Pleural Mesothelioma
4. Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers
5. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial
6. NTRK gene fusion testing and management in lung cancer
7. New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe
8. Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer
9. Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective
10. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries
11. Antibodies against endogenous retroviruses promote lung cancer immunotherapy
12. A tailored approach to horizon scanning for cancer medicines
13. Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
14. Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
15. MesoGraph: Automatic profiling of mesothelioma subtypes from histological images
16. Malignant Mesothelioma subtyping via sampling driven multiple instance prediction on tissue image and cell morphology data
17. Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping
18. The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care
19. Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies
20. RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome
21. Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives
22. Malignant Mesothelioma Subtyping of Tissue Images via Sampling Driven Multiple Instance Prediction
23. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
24. Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202).
25. FURVENT: Phase 3 trial of furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).
26. Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor.
27. Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
28. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial
29. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study
30. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743
31. The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment: Including myocarditis and the new entity of non inflammatory left ventricular dysfunction
32. Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer
33. Author Correction: Integrated genomics point to immune vulnerabilities in pleural mesothelioma
34. A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer
35. Targeting un-MET needs in advanced non-small cell lung cancer
36. Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)
37. 119 Estimating the health benefits of introducing ctDNA next generation sequencing to the diagnostic pathway for advanced lung cancer: A modelling study
38. 19 Utility of blood tests after completion of maintenance durvalumab after radical chemo-radiotherapy in patients with Non Small Cell Lung Cancer stage III
39. 48 Real world outcomes of a lung cancer genomic tumour advisory board: a single-centre experience in the United Kingdom
40. 7 Concordance of MET amplification detection between FISH and NGS in NSCLC
41. 81 Evaluation of neoadjuvant chemo-immunotherapy for operable non-small cell lung cancer: clinical outcomes and impact on service delivery
42. Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India
43. Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 – Systematic review and meta-analysis
44. Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists
45. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer
46. Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations
47. Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies
48. Malignant Mesothelioma Subtyping of Tissue Images via Sampling Driven Multiple Instance Prediction
49. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma
50. Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.